Nintedanib esylate (Standard)

Nintedanib esylate (Standard) is the analytical standard of Nintedanib esylate. This product is intended for research and analytical applications. Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

Product Specifications

CAS Number

[656247-18-6]

Product Name Alternative

BIBF 1120 (esylate) (Standard)

UNSPSC

12352005

Hazard Statement

H360-H372-H411

Target

FGFR; PDGFR; Reference Standards; VEGFR

Type

Reference Standards

Related Pathways

Others; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nintedanib-esylate-standard.html

Smiles

O=C(C1=CC(NC/2=O)=C(C=C1)C2=C(NC3=CC=C(N(C)C(CN4CCN(C)CC4)=O)C=C3)/C5=CC=CC=C5)OC.CCS(=O)(O)=O

Molecular Formula

C33H39N5O7S

Molecular Weight

649.76

Precautions

P260-P264-P270-P273-P280-P391-P405-P501

References & Citations

[1]Hilberg F, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res, 2008, 68 (12), 4774-4782.|[2]Roth GJ, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120) . J Med Chem, 2009, 52 (14), 4466-4480.|[3]Suzuki N, et al. Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts. Oncol Rep. 2016 Dec;36 (6) :3123-3130.